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During embryogenesis, the Activin/Nodal pathway
promotes the mesendodermal lineage and inhibits
neural fate. The molecular mechanisms underlying
this role of the Activin/Nodal pathway are not clear.
In this study, we report a role for protein tyrosine
phosphatase 1B (PTP1B) in Activin-mediated early
fate decisions during ESC differentiation and show
that PTP1B acts as an effector of the Activin pathway
to specify mesendodermal or neural fate. We found
that the Activin/ALK4 pathway directly recruits
PTP1B and stimulates its release from the endo-
plasmic reticulum through ALK4-mediated cleavage.
Subsequently, PTP1B suppresses p-ERK1/2 sig-
naling to inhibit neural specification and promote
mesendodermal commitment. These findings sug-
gest that a noncanonical Activin signaling pathway
functions in lineage specification of mouse and
human embryonic stem cells.
INTRODUCTION
Activin/Nodal, members of the transforming growth factor-b
(TGF-b) superfamily, exhibit various roles during different stages
of embryogenesis. The Activin/Nodal pathway maintains the
undifferentiated status of the epiblast in mice (Mesnard et al.,
2006), which coincides with the in vitro role of Activin in sustain-
ing the pluripotency of mouse and human embryonic stem cells
(ESCs) (Ogawa et al., 2007; Vallier et al., 2005). As development
proceeds, the Activin/Nodal pathway plays a crucial role in line-
age decisions. In vivo studies showed that different concentra-
tions of Activin elicit distinct responses from Xenopus animal
caps, ultimately producing a range of mesodermal fates (Green
and Smith, 1990). Nodal/mice fail to form both the mesoderm
and the definitive endoderm but show precocious neural differ-
entiation (Camus et al., 2006), suggesting that the Activin/Nodal
pathway promotes the mesendodermal lineage and inhibits neu-
ral fate. Furthermore, inhibition of Activin signaling has been
shown to promote neural fate in human ESCs and induced
pluripotent stem cells (iPSCs) (Smith et al., 2008; Chambers706 Cell Stem Cell 13, 706–719, December 5, 2013 ª2013 Elsevier Inet al., 2009). The action in which the Activin/Nodal pathway pro-
motes mesendodermal fate over neural fate has begun to be
investigated. Chng et al. (2010) recently suggested that Activin/
Nodal signaling acts through Smad-interacting protein 1 (SIP1)
to regulate the cell-fate decision between neuroectoderm and
mesendoderm fates. However, the precise molecular mecha-
nisms underlying the specification of mesendodermal fate and
the inhibition of neural fate by the Activin/Nodal pathway remain
to be elucidated.
Activin exerts its effect by initially binding to the type II Activin
receptor (ACVRIIB), then recruiting and phosphorylating the type
I receptor (ALK4), which in turn phosphorylates and activates
SMAD2. SMAD2 then forms a complex with SMAD4 and trans-
locates to the nucleus to regulate gene transcription (Werner
and Alzheimer, 2006). In a screening, we have identified
PTP1B as an effector in the Activin/Alk(ALK)4 pathway. PTP1B
is a widely expressed nonreceptor protein tyrosine phosphatase
that is located in the endoplasmic reticulum (ER) (Frangioni et al.,
1992). It can directly dephosphorylate and inactivate a diverse
range of substrates, including receptor protein tyrosine kinases
(RPTKs; e.g., insulin receptor [IR], epidermal growth factor
receptor [EGF-R], platelet derived growth factor receptor, and
insulin-like growth factor receptor), components of growth factor
pathways (e.g., Jak2, p63DOK, and Src), and SH3-containing
proteins (e.g., p130Cas, Fak, and Crk), which have critical roles
in integrin signaling (Dadke and Chernoff, 2002; Bourdeau
et al., 2005). PTP1B has also been shown to decrease levels of
p-Erk1/2 in various studies (Ferrari et al., 2011; Haj et al.,
2003). PTP1B plays a role in diabetes (Combs 2010), obesity
(Bence et al., 2006), cancer (Julien et al., 2007; Bentires-Alj
and Neel, 2007), and cell proliferation (Arias-Salgado et al.,
2005).
Here, we show that PTP1B is recruited to Alk(ALK)4 and forms
part of a noncanonical Activin signaling pathway that controls
mesendoderm or neuroectoderm lineage specification.
RESULTS
The Activin/Alk(ALK)4 Pathway Induces
Mesendodermal Fate and Suppresses Neural Fate
We sought to determine the role of Activin in cell fate decision at
different stages of mouse and human ESC differentiation. To this
end, both hESCs and mESCs were transferred to N2B27c.
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after 1 day of differentiation (1Activin), 2 days of differentiation
(2Activin), or 3 days of differentiation (3Activin). The cells were
then allowed to differentiate for either 6 (mESCs) or 8 (hESCs)
days in the continued presence of Activin (Figure S1Aavailable
online). In mESCs, we found that 1Activin sustained more than
60% of the gene expression levels of Oct4 and Nanog during
the 6 days of differentiation, while the expression levels of the
two genes dropped below 5% in nontreated cells (Figure 1A).
Of note, 1Activin did not maintain the expression of another
pluripotent marker, Rex1 (Figure 1A). However, 1Activin
enhanced the expression of Fgf5, a marker of epiblast cells (Fig-
ure 1A). Our findings suggest that Activin promotes the develop-
ment of epiblast cells frommESCs. As differentiation proceeded,
the Activin treatments (2Activin and 3Activin) exhibited less
effect on the expression levels of Oct4, Nanog, and Fgf5 in
mESCs (Figure 1A), suggesting that the effect of Activin on
pluripotency is restricted to a certain time window during ESC
differentiation. We also examined the impact of Activin on other
lineages during differentiation. We found that Activin treatment
promoted mesendodermal fate specification as judged by
T and T expression (Figures 1A and S1B), while only 1Activin
inhibited primitive endoderm (Gata 6), trophectoderm (Cdx2),
endoderm (Hnf4 and Afp), and neuroectoderm (Sox1) fates
(Figure 1A).
Activin also exhibited a similar pattern of effects in hESCs, with
a few exceptions. During the 8 days of hESC differentiation,
1Activin maintained high OCT4 expression (Figure 1B). Interest-
ingly, 1Activin resulted in more than a 2-fold increase in the
expression levels of NANOG throughout the 8 day differentiation
period, far greater than that seen in mESCs (Figures 1A and 1B).
Because Nanog is expressed in ESCs and epiblast cells (Mitsui
et al., 2003), our results suggest that the high expression levels
of NANOG in hESCs induced by Activin may represent an
epiblast stage. However, FGF5 expression was hardly detected
in all groups of cells (data not shown). As in mESCs, 1Activin also
promoted mesendodermal (T, T, and SOX17) and inhibited neu-
roectodermal (PAX6) fate specification (Figures 1B, 1C, and
S1B). The reason we used PAX6 rather than SOX1 to identify
human neuroectoderm is because PAX6 is expressed earlier
than SOX1,which shows a reciprocal expression order in mouse
and human (Figure S1C). Furthermore, there were extremely low
levels of expression for the phenotypic markers of primitive
endoderm, trophectoderm, and endoderm (data not shown).
Interestingly, 2Activin and 3Activin not only exhibited less effect
on the promotion of themesendodermal phenotype but also alle-
viated the inhibition of other cell fates in mESCs and hESCs (Fig-
ures 1A and 1B). Our results suggest that Activin-mediated early
fate decision in ESCs occurs in the first 2 days of differentiation.
In summary, as ESC differentiation proceeds, Activin promotes
mesendodermal fate while inhibiting neural specification, which
may occur via p-Smad(SMAD)2 signaling (Figure 1D).
Blockade of the Activin/Alk(ALK)4 Pathway with
SB431542 Promotes Neural Lineage
We showed that mESCs in which neuronatin was knocked down
(Nnat-KD) fail to undergo neural induction and are possibly trap-
ped at the epiblast stage (Lin et al., 2010). This was concluded
because Nnat-KD mESCs exhibited very high Fgf5 expressionCelland resisted differentiation. We used the Nnat-KD mESCs to
investigate how the inhibition of the Activin/Alk4 pathway affects
neural induction. We treated Nnat-KD mESCs, at different days
of differentiation (Figure S1A), with one dose of SB431542, a
selective inhibitor of Activin/Nodal signaling that acts at ALK4/
5/7 to block the downstream p-Smad2/3 signaling cascade (In-
man et al., 2002). Intriguingly, we found that +0SB43 or +1SB43
treatment restored the ability of Nnat-KD mESCs to undergo
neural induction to levels seen in wild-type mESCs, as
assayed by Sox1-GFP expression (Figure 2A). Interestingly,
SB431542 failed to rescue neural induction of Nnat-KD mESCs
when administered to cells after 2 days of differentiation
(i.e., +2SB43 and +3SB43). We also found that the capacity of
Nnat-KD mESCs to produce neurons after +1SB43 treatment
was restored to that of wild-type cells (Figure 2B). Our results
suggest that blocking the Activin/Alk4 pathway rescues neural
induction in Nnat-KD mESCs and that the efficacy of this treat-
ment is restricted to the first 2 days of differentiation, echoing
the findings shown in Figure 1A.
We further tested whether inhibition of the Activin/Alk4
pathway also promotes neural fate in wild-type mESCs. It has
been reported that cells plated at high densities fail to adopt
the neural fate, possibly due to inhibitory signals from cell-to-
cell contact (Zhou et al., 2008). We adopted a high-density
culture system to investigate the effect of SB431542 on neural in-
duction. Cells were plated at a standard density (3 3 104 cells/
cm2) and at high density (36 3 104 cells/cm2) and were driven
toward neural differentiation in the presence or absence of
SB431542. Interestingly, we found that SB431542 had no posi-
tive effects on the production of neural stem cells (NSCs) at stan-
dard density. However, SB431542 caused a significant increase
in the number of NSCs under high-density conditions (Figure 2C),
indicating that the Activin/Alk4 pathway exerts an inhibitory
effect on neural induction in mESCs, which is also corroborated
by our other finding that Activin treatment prevented mESCs
from adopting a neural fate (Figure S2A).
We further examined whether the inhibition of the Activin/Alk4
pathway also induces neural specification in hESCs. We
observed a distinctive difference in neural specification between
hESCs and mESCs in our system. Mouse ESCs are capable of
generating over 60% NSCs when undergoing neural differentia-
tion in N2B27medium. However, fewer than 5% of cells became
NSCswhen hESCswere driven to the neural lineage. Intriguingly,
in the presence of SB431542, NSC formation was significantly
enhanced for hESCs, as judged by the number of neural rosettes
and expression levels of PAX6 (Figures 2D and 2E), suggesting
that the Activin/Alk(ALK)4 pathway plays an inhibitory effect on
neural induction in both hESCs and mESCs and that the effect
is functionally specific in neural fate decision (Figure S2B).
Collectively, the inhibition of Activin/Alk(ALK)4 signaling by
SB431542 leads to neural induction in ESCs, which may be
due to either SB431542 inhibiting p-Smad(SMAD)2 signaling or
an unknown pro-neural-inducing influence of SB431542, or a
combination of both of these mechanisms (Figure 2F).
SB431542 Promotes Neural Fate via p-Erk(ERK)1/2
Signaling
We sought to identify the mechanism underlying SB431542-
mediated neural induction. In an accidental discovery, we foundStem Cell 13, 706–719, December 5, 2013 ª2013 Elsevier Inc. 707
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Figure 1. Activin Promotes either Pluripotency or Mesendodermal Fates while Inhibiting Neural Fate
During (A) mESC and (B) hESC differentiation, expression levels of stage-specific genes in the presence of stage-dependent treatments of Activin were
measured by quantitative real-time PCR. Activin was administered to cells continuously from 1-day (1Activin), 2-day (2Activin), or 3-day (3Activin) differentiation.
(legend continued on next page)
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p-Erk1/2 levels, which peaked after 10 min of treatment and
lasted for 2 hr after treatment (Figures 3A and S3A). We also
observed a similar outcome in hESCs; however, the elevated
levels of p-ERK1/2 returned to control levels after 1 hr (Fig-
ure 3B). These results suggest that SB431542 not only
inhibited p-Smad2/3 signaling but also activated p-Erk(ERK)1/
2 signaling.
Next, we determinedwhether SB431542-triggered p-Erk(ERK)
1/2 signaling is involved in SB431542-mediated neural induction.
To this end, we examined the effects of p-Erk1/2 signaling
inhibitors (PD173074 [a FGFR inhibitor] and PD184352 [a MEK
inhibitor]) on SB431542-restored neural induction in Nnat-KD
mESCs at different time points during differentiation. We found
that, after SB431542 treatment, 89% of the colonies generated
by Nnat-KD mESCs were Sox1/eGFP+ NSCs at 6 days of differ-
entiation, and those Sox1/eGFP+ colonies were completely
abolished when the cells were cotreated with SB431542 and
PD184352 (i.e., +1SB43+1PD18) (Figures 3C and S3B). Interest-
ingly, the later stages of PD184352 treatments (e.g., +2PD18,
+3PD18, and +4PD18) sustained the inhibitory effect on neural
induction, suggesting that SB431542-mediated neural induction
in Nnat-KD ESCs is via p-Erk1/2 signaling. A very similar effect
was also observed in control cells treated with PD184352 (Fig-
ure 3C), indicating that p-Erk signaling is indeed crucial in
SB431542-mediated neural induction. These data were also
corroborated using another inhibitor, PD173074, which inhibited
neural induction in control and Nnat-KD ESCs less potently
(Figure 3D).
The importance of p-Erk1/2 signaling in SB431542-promoted
neural induction is also corroborated by our findings in hESCs.
We found that, in the absence of SB431542, hESCs underwent
neural induction at low efficiency, with less than 5% of the
colonies generated containing NSCs (Figure 3E); SB431542
treatment enhanced neural induction in hESCs over seven times
that seen in untreated cells. SB431542-mediated neural induc-
tion in hESCs was also inhibited by PD184352 and PD173074,
similar to our findings in mESCs (Figures 3E and 3F), suggesting
that the role of FGF/p-ERK signaling in neural induction is
conserved in hESCs. Taken together, our results suggest that
SB431542 exerts dual effects by activating p-Erk(ERK)1/2
signaling and inhibiting p-Smad(SMAD)2/3 signaling, with
SB431542-mediated p-Erk(ERK)1/2 signaling promoting neural
lineages in mESCs and hESCs (Figure 3G).
SB431542 Activates p-Erk1/2 Signaling by Antagonizing
a Noncanonical Activin Pathway
We next analyzed whether SB431542 increased p-Erk(ERK)1/2
levels through its inhibitory action on the Activin/Alk(ALK)4) path-
way or through its effect on the FGF/p-Erk(ERK)1/2 pathway.
First, we tested whether Activin reduces p-Erk(ERK)1/2 levels
in ESCs as a premise that the inhibition of Activin pathway leads
to an increase in p-Erk(ERK)1/2 level. We found that Activin not
only activated p-Smad2 signaling but also inhibited p-Erk1/2Stage-specific markers indicate pluripotency (Rex1, Oct4/OCT4, and Nanog/N
mesendoderm (T), neuroectoderm (Sox1/PAX6), and definitive endoderm (Hnf4/A
values of cyclophilin and GAPDH for mESCs and hESCs, respectively. (C) The e
schematic diagram summarizing data. See also Figure S1.
Cellsignaling in mESCs (Figure 4A). However, in the presence of
SB431542, p-Erk1/2 levels increased despite treatment with
Activin (Figure 4A), suggesting that, in part, SB431542 triggers
an increase in p-Erk1/2 levels by acting upon components of
the Activin/Alk4 signaling pathway. We also observed that
Activin attenuated the levels of p-ERK1/2 in hESCs using a
phospho-mitogen activated protein kinase (phospho-MAPK)
array assay (Figure 4B). Strikingly, among the 18 phospho-
MAPKs tested, only the levels of p-ERK1/2 were affected by
SB431542 or Activin treatments (Figure S4).
We further established if the increased p-Erk1/2 levels are due
to the inhibition of p-Smad2 by SB431542.We found that, in both
control and Nnat-KD mESCs, the levels of p-Erk1/2 peaked
10 min after SB431542 treatment, whereas p-Smad2 levels
were only reduced after 2 hr of treatment (Figures 4C and 4D).
We also observed that SB431542 exhibited no effect on the
BMP4/p-Smad1 pathway (Figures 4C and 4D). Our data show
that SB431542-triggered p-Erk1/2 signaling precedes the inhibi-
tion of p-Smad2 signaling, suggesting that SB431542-mediated
p-Erk1/2 signaling is not caused by the inhibition of p-Smad2,
p-Smad1, or their downstream components but possibly by
upstream elements of the Activin pathway (e.g., Alk4). It is
conceivable that SB431542-triggered p-Erk(ERK)1/2 signaling
results from crosstalk between SB431542 and the FGF/p-
Erk(ERK)1/2 pathway. To test this, we employed a biochemical
approach using PD173074 and PD184352. We found that the
SB431542-mediated increase in p-Erk(ERK)1/2 levels was abol-
ished in the presence of PD173074 or PD184352 in both mESCs
and hESCs (Figure 4E), indicating that the FGF/p-Erk(ERK)1/2
pathway is involved in this process. To determine how the
FGF/p-ERK1/2 pathway is involved in the effect of SB431542,
we screened a phospho-receptor tyrosine kinase (phospho-
RTK) array containing upstream elements of p-ERK1/2 signaling
with proteins from SB431542-treated ESCs. We found that none
of the 42 tested phospho-RTKs was affected by SB431542 treat-
ment when compared to the dimethyl sulfoxide (DMSO)-treated
control group (Figure 4F), indicating that SB431542-mediated
p-ERK1/2 signaling does not act at the level of RTKs. In general,
our results suggest that SB431542-triggered p-Erk(ERK)1/2
signaling possibly occurs via antagonizing a noncanonical
pathway of Activin that negatively regulates p-Erk(ERK)1/2 levels
(Figure 4G).
PTP1B Is a Key Effector in an Activin/ALK4
Noncanonical Pathway to Suppress p-ERK1/2 Signaling
We have shown that Activin inhibits p-Erk(ERK)1/2 signaling and
that this inhibition is not due to the downstream action of
p-Smad2 signaling. Thus, we sought to determine how Activin
mediates inhibition of p-Erk(ERK)1/2 signaling in ESCs. In a
broader screening, we discovered that PTP1B is a putative
member of the Activin/Alk(ALK)4 pathway that mediates the inhi-
bition of p-Erk(ERK)1/2 signaling. First, we established that
Alk(ALK)4 interacts with PTP1B in mESCs and hESCs using a
proximity ligation assay (PLA). Using this assay, numerousANOG), epiblast (Fgf5), primitive endoderm (Gata6), trophectoderm (Cdx2),
fp). All data are represented as mean ± SD (n = 2) and were normalized to the
xpression of SOX17, a marker for mesendoderm, was detected by PCR. (D) A
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Figure 2. Inhibition of the Activin/Alk(ALK)4 Pathway by SB431542 Promotes the Neural Lineage
(A) Immunocytochemical analysis (ICC; left panel) shows that SB431542 restores neural induction in Nnat-knockdown (Nnat-KD) mESCs, judging by the pro-
duction of Sox1-eGFP+/Nestin+ (red) neural stem cells. SB431542 was administered to the cells on the same day as differentiation induction (+0SB43) or 1-day
(+1SB43), 2-day (+2SB43), or 3-day (+3SB43) differentiation. The right panel shows the quantified data.
(legend continued on next page)
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ing that Alk(ALK)4 and PTP1B are physically interacting (Fig-
ure 5A). This interaction was further confirmed by coimmunopre-
cipitation (Figure S5A). We serendipitously observed that
incubating active recombinant ALK4 and recombinant PTP1B
together at 30C resulted in the apparent cleavage of PTP1B
(Figure 5B). To determine whether this cleavage also occurs
within a cellular context, we treated hESCs with Activin for
various time periods and determined what effects this treatment
had on the integrity of endogenous PTP1B. We found that
PTP1Bwas cleaved after 30 min of Activin treatment (Figure 5C),
suggesting that Activin causes an interaction between ALK4 and
PTP1B that leads to the cleavage of PTP1B by ALK4. We have
shown that ALK4 has a protease activity; to our knowledge,
PTP1B is the first of its substrates to be identified. Furthermore,
treating hESCs with Activin causes PTP1B to translocate from
the ER to the cytosol (Figure S5B) and then to cell membrane
(Figure S5C), suggesting that PTP1B is cleaved and not
degraded. Because ALK4 is a serine/threonine kinase receptor,
we examined whether ALK4 affects the phosphorylation status
of PTP1B by employing LC/MS/MS protein sequencing. The
sequencing data showed that residue Lys292 is the last residue
detected in the C-terminal region of PTP1B after incubation with
ALK4 (band 3 in Figure 5D). We propose that the possible cleav-
age site for active ALK4 on PTP1B is located between the resi-
dues Glu293 to Arg371. Interestingly, no serine or threonine
phosphorylation was identified (Figure 5D).
It is conceivable that PTP1B could physically interact with
p-Erk(ERK)1/2 to exert its effect. Intriguingly, we not only
found that PTP1B indeed interacted with p-Erk(ERK)1/2, but
also discovered that treating ESCs with Activin significantly
increased the number of interactions between PTP1B and
p-ERK1/2. Conversely, treatment with SB431542 significantly
decreased the interaction of these two proteins (Figure 6A). As
PTP1B is a phosphatase, it is likely that the interaction between
PTP1B and p-ERK1/2 would result in the dephosphorylation of
p-ERK1/2. To confirm this, we immunoprecipitated PTP1B
from Activin-treated hESCs, incubated it with total protein ex-
tracts from hESCs, and then analyzed p-ERK1/2 levels by west-
ern blot. We found that the levels of p-ERK1/2 were diminished
proportionally to the duration of incubation with PTP1B (Fig-
ure 6B), indicating that PTP1B dephosphorylates p-ERK1/2.
We also found a similar role for PTP1B in mESCs (Figure S6A).
Our results suggest that Activin (via ALK4) decreases p-ERK1/
2 levels by releasing PTP1B from the ER, allowing it to interact
with and dephosphorylate p-ERK1/2, thus inhibiting neural
fate. If our hypothesis that PTP1B dephosphorylates p-ERK1/2
to prevent neural induction is correct, then this interaction
should not occur once neural induction has taken place. We
found that PTP1B/p-ERK1/2 interactions (indicated in red(B) SB431542-restored neuron production in Nnat-KD mESCs by ICC analysis (l
(C) In mESCs, SB431542 prevents an inhibitory effect on neural induction mediate
(right panel).
(D and E) In hESCs, SB431542 enhances (D) neural rosette formation identified
differentiation, as assessed by quantitative real-time PCR.
(F) A schematic diagram summarizing data.
Scale bars represent 50 mm, except 100 mm in (D). Data shown are the mean ± S
significantly different from the SB431542-untreated cells; two-tailed Student’s t
Celldots) were abundantly present in undifferentiated hESCs and
in cells after 2 days of differentiation; however, the interaction
diminished sharply after 4 days and was absent by 6 days of
differentiation (Figure 6C), which coincides with the onset of
neural induction. Strikingly, we observed that SOX1+ neural
rosettes were virtually devoid of PTP1B/p-ERK1/2 interactions,
while the interactions were prevalent in non-NSCs (Figure 6C),
suggesting that PTP1B/p-ERK1/2 interactions are not present
in NSCs, consistent with our theory. Furthermore, a similar
pattern was observed during mESC-derived neural differentia-
tion (Figure 6D), indicating that the role of p-Erk(ERK)1/2 in
neural induction of ESCs is conserved in human and mouse.
We established that the lack of PTP1B/p-ERK1/2 interactions
in NSCs is not due to the absence of these two proteins,
because PTP1B and p-ERK1/2 proteins were clearly observed
in neural rosettes by immunocytochemical analysis (ICC; Fig-
ure S6B). We propose that this can be explained by the absence
of Activin signaling in neural cells. Indeed, ALK4 was present in
ESCs and nonneural cells but was absent in neural rosettes (Fig-
ure S6C). In summary, our results show that Alk(ALK)4 recruits
and cleaves PTP1B, which then dephosphorylates p-ERK1/2,
leading to the inhibition of neural induction. SB431542-mediated
neural induction takes place by counteracting the effect of
PTP1B (Figure 6E).
PTP1B Bypasses the Activin Pathway to Specify
Mesendodermal Fate over Neural Fate
To precisely elucidate the role of PTP1B as a downstream
effector of the Activin pathway, we employed gain-of-function
and loss-of-function approaches to investigate the effects of
PTP1B on the early fate decisions of ESCs. We generated
control-KD, PTP1B-knockdown (PTP1B-KD), PTP1B/eGFP-
overexpression (PTP1B-OE), and control-OE hESC (eGFP only)
lines; expression levels of PTP1B were verified by western blot
(Figure 7A). We also showed that the levels of PTP1B exhibited
an inverse relationship with the levels of p-ERK1/2 (Figures 7A
and S7A) in cells, which corroborates with our findings in Fig-
ure 6B. In characterizing PTP1B mutant ESCs, we found there
is no discernible difference in the expression of pluripotent
markers NANOG or OCT4 in ES medium. However, we found
that PTP1B-KD hESCs showed a propensity for the neural fate
and a decrease in mesendodermal phenotypes as compared
to the control group, judged by the expression of neural markers
(PAX6 and SOX1) and mesendodermal markers (SOX17, GSC,
PDGFRa, T, and PECAM1) (Figure 7B). We also found that
knocking down PTP1B significantly enhanced PAX6+ NSC pro-
duction in the absence of SB431542 by 4-fold in three separate
PTP1B-KD clones compared to the control (Figure 7C). PTP1B-
KD also increased the capacity of hESCs to produce neural
rosettes (data not shown). Furthermore, we also found thateft panel) and quantified data (right panel) are shown.
d by high-density plating shown by ICC analysis (left panel) and quantified data
by PAX6 (green)/ZO-1 (red) staining and (E) PAX6 expression during neural
D (n = 3). **p < 0.01, significantly different from the control group; ##p < 0.01,
test. See also Figure S2.
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Figure 3. SB431542-Mediated Neural Induction Occurs via p-Erk(ERK)1/2 Signaling
(A and B) The duration of SB431542 treatment results in an increase in p-Erk(ERK)1/2 levels as measured by western blot.
(C and D) The temporal effects of PD184352 (a MEK inhibitor) and PD173074 (a FGFR inhibitor) on SB431542-restored neural induction in mESCs. The top
panel depicts the differentiation status of cells. The values are the percentages of Sox1-eGFP+ colonies at 6 days of differentiation and are presented as mean ±
SD (n = 3). ‘‘+1,’’ ‘‘+2,’’ ‘‘+3,’’ and ‘‘+4’’ indicate the timing of the treatment: continuously from 1, 2, 3, and 4 days after differentiation, respectively. Cell survival
rates after inhibitor treatments are in brackets. *p < 0.05 and **p < 0.01 are significantly different from the group without drug treatment.
(E and F) PD184352 (E) and PD173074 (F) inhibit SB431542-induced neural induction in hESCs. ICC analysis is shown in the left panel and quantified data, in the
right panel. Data are presented as mean ± SD (n = 2). Scale bars represent 50 mm.
(G) A schematic diagram summarizing the data. See also Figure S3.
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PTP1B Specifies Neural or Mesendodermal FateNnat-KDmESCs treated with PTP1B inhibitor restored the ability
of these cells to undergo neural induction (Figure S7B), suggest-
ing that PTP1B exhibits a negative effect on neural lineages in
hESCs and mESCs. On the contrary, PTP1B-OE ESCs were
biased toward mesendodermal lineages and exhibited a
diminished capacity to adopt neural fates (Figures 7B and 7D).
Of note, control and PTP1B-KD ESCs showed an enhancement712 Cell Stem Cell 13, 706–719, December 5, 2013 ª2013 Elsevier Inin their ability to generate mesendodermal fates and an inhibi-
tion of neural specification with Activin treatment, while
PTP1B-OE hESCs exhibited very similar profiles ofmesendoder-
malmarkers to those of Activin-treated cells (Figures 7B and 7D),
indicating that PTP1B takes part in Activin-promoted mesendo-
dermal decision, possibly in cooperation with p-Smad(SMAD)2
signaling.c.
A B
C D
E F
G
Figure 4. SB431542-Mediated p-Erk1/2 Sig-
naling Precedes the Inhibition of p-Smad2
Signaling
(A) The levels of p-Erk1/2 and p-Smad2 change
after 10min of Activin and/or SB431542 treatment.
(B) Activin and SB431542 affect the levels of
p-ERK1/2 in hESCs as assayed in a phospho-
MAPK array. In (C) control and (D) Nnat-KD
mESCs, the duration of SB431542 treatment
affects the levels of p-Erk1/2, p-Smad2, and
p-Smad1. (E) The effects of PD173074 or
PD184352 on the SB431542 elevation of
p-Erk(ERK)1/2 levels in ESCs. (F) The effect of
SB431542 on 42 phospho-RTKs measured with
a phospho-RTK array. (G) A schematic diagram
summarizing the data. See also Figure S4.
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PTP1B Specifies Neural or Mesendodermal FateWe also observed an interesting phenomenon reported by
Rodriguez et al. (2007) that high levels of Oct4 expression
coincided with upregulated differentiated markers. Our data
show that Activin sustained high-level expression of pluripotent
markers OCT4 and NANOG during 8-day differentiation and
concurrently upregulated mesendodermal markers (Figure 7B),
which correlates with our findings shown in Figure 1. Intrigu-
ingly, although the sustained high-level expression of OCT4
and NANOG was not seen in PTP1B-OE hECSs (Figure 7B),
we did find that several colonies with high OCT4- and
NANOG-expressing cells were observed in 8-day differentiation
culture and colocalized with the groups of cells that highly ex-
pressed PTP1B-eGFP but not those that expressed eGFP
alone (Figures S7C and S7D). We also employed a chemically
defined culture (CDC) system to establish that the results
derived from our study are not specific to the N2B27 culture
system we have used. Our results showed that SB431542
also increased the levels of p-ERK1/2 from a 10 min treatment
in CDC system (Figures S7Ea), which is consistent with those
observed in the N2B27 system. Moreover, PTP1B-KD pro-
motes hESCs undergoing neural induction to a similar rate un-Cell Stem Cell 13, 706–719, Dder SB431542 treatment, whereas only a
few of the control-KD cells adopted neu-
ral fate (Figures S7Eb), suggesting that
the effect of PTP1B on neural induction
is not limited to the N2B27 medium,
but also exists in CDC system. Like in
N2B27 medium, the SB431542-
mediated neural induction was blocked
by FGF/p-ERK1/2 inhibitors in CDC sys-
tem (Figure S7Ec). In summary, we
found that Activin leads to the cleavage
of PTP1B by active Alk(ALK)4 and
enhances the interaction between
PTP1B and p-Erk(ERK)1/2, which results
in a reduction in p-Erk(ERK)1/2 levels,
which in turn inhibits neural induction in
favor of a mesendodermal fate, possibly
in collaboration with p-Smad(SMAD)2
signaling (Figure 7E). Conversely,
SB431542 inhibits p-Smad(SMAD)2 sig-
naling, blocks PTP1B/p-Erk(ERK)1/2interactions, and triggers p-Erk(ERK)1/2 signaling, which pro-
motes neural specification (Figure 7E).
DISCUSSION
Embryonic development is controlled by intricate networks that
include cytokines, transcription factors, and other regulatory
elements. Cytokines induce myriad intracellular activities,
including the activation or inhibition of multiple signal transduc-
tion pathways, culminating in phenotypic specification. Activin
and Nodal play crucial roles during different stages of embryo-
genesis (Green and Smith, 1990; Camus et al., 2006; Vallier
et al., 2004; Singh et al., 2012). Our study demonstrates that
PTP1B takes part in the Activin-directed choice betweenmesen-
doderm and neuroectoderm. PTP1B exerts its role in this
early fate decision possibly by mediating a noncanonical Activin
pathway.
Our study shows that inhibition of Activin signaling using
SB431542 leads to neural differentiation in hESCs and mESCs,
which is consistent with previous studies in hESCs (Smith
et al., 2008; Chambers et al., 2009). To define the molecularecember 5, 2013 ª2013 Elsevier Inc. 713
AB C
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Figure 5. Activin Induces PTP1B Cleavage through Alk(ALK)4
(A) The physical interaction between Alk(ALK)4 and PTP1B (indicated by red dots) in ESCs detected by PLA.
(B) Dose-dependent cleavage of recombinant PTP1B by constitutively active recombinant ALK4 after 15 min incubation at 30C.
(C) ImmunoblotdetectionofPTP1Bcleavage inhESCstreatedwithActivin for various timeperiods. ImageJwasemployed toquantify thecleavedbands (inBandC).
(D) Sodium dodecyl sulfate polyacrylamide gel electrophoresis of the cleavage products of the ALK4/PTP1B reaction. The schematic diagram depicts the
potential cleaved region of PTP1B by ALK4 with the amino acid sequence shown in red to indicate the possible cleavage site as identified by protein sequencing.
See also Figure S5.
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PTP1B Specifies Neural or Mesendodermal Fatemechanisms underlying SB431542-mediated neural induction in
ESCs, we uncover that the inhibition of the Activin/ALK4 pathway
by SB431542 not only inhibits p-SMAD2/3 signaling but also ac-714 Cell Stem Cell 13, 706–719, December 5, 2013 ª2013 Elsevier Intivates p-Erk(ERK)1/2 signaling. We corroborated this finding by
screening human phospho-MAPKs more broadly. We have
found that SB431542 treatment only increases the levels ofc.
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Figure 6. Activin Inhibits Neural Differentiation by Reducing p-ERK1/2 Levels through PTP1B
(A) Activin increases the number of interactions between PTP1B and p-ERK1/2 (indicated by red dots), which was blocked by SB431542 treatment (left panel).
Quantified data are shown in the right panel and presented as mean ± SD (n = 3). *p < 0.05 and **p < 0.01, significantly different from the DMSO-treated control
cells; ##p < 0.01, significantly different from the Activin-treated cells.
(B) PTP1B dephosphorylates p-ERK1/2 in a time-dependent manner, as demonstrated by PTP1B (+PTP1B/IP) pull-down with FGF2-stimulated p-ERK (left
panel). Phospho-ERK1/2 was not dephosphorylated when incubated with nonenriched PTP1B (PTP1B/IP) (right panel).
(C and D) The interaction between PTP1B and p-ERK during neural differentiation in hESCs (C) and mESCs (D) detected by PLA.
(E) A schematic diagram summarizing data.
Scale bars represent 50 mm. See also Figure S6.
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Figure 7. PTP1B Promotes Mesendodermal Fates and Restricts Neural Differentiation
(A) PTP1B hESC mutants were verified by western blot and their effects on the levels of p-ERK1/2.
(B) The expression profiles of fate markers in PTP1B mutant hESCs as assessed by RT-PCR.
(C) Three PTP1B-KD hESC clones were subjected to neural differentiation in the absence of SB431542, and PAX6+ cells (red) were counted. Data are presented
as mean ± SD (n = 3). **p < 0.01, significantly different from the control group.
(D) PTP1B-eGFP-overexpressing hESCs favor mesendodermal fate, judging by SOX17 expression.
(E) A schematic diagram depicts the conceptual summary derived from this study.
Scale bars represent 50 mm. See also Figure S7.
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PTP1B Specifies Neural or Mesendodermal Fatep-ERK1/2 and not those of 17 other tested kinases, demon-
strating that SB431542-mediated p-ERK1/2 signaling is specific.
We also show that SB431542 elevation of p-Erk(ERK)1/2 levels is
dependent on neither SB431542 inhibition of p-SMAD2/3
signaling nor involvement of p-SMAD1 signaling. However, we
demonstrate that the p-Erk(ERK)1/2 effect of SB431542 is acting
upon the Activin/Alk(ALK)4 pathway, perhaps via a noncanonical
pathway of Activin. In the past decade, many studies have high-
lighted crosstalk between TGF-b1 signaling via Smads and the
MAPK pathway (Li et al., 2009; Jiang et al., 2010). To rule out
the possibility that crosstalk between SB431542 and the FGF
pathway might be involved in SB431542-mediated p-Erk(ERK)
1/2 signaling, we analyzed a phospho-RTK array and found
that none of the tested phospho-RTKs was affected by
SB431542 treatment. However, we did find that FGF/p-Er-
k(ERK)1/2 signaling inhibitors abolish the SB431542-mediated
p-Erk(ERK)1/2 elevation, indicating that p-Erk(ERK)1/2 is the
convergence point of the SB431542 actions. We propose that
SB431542 counteracts a noncanonical pathway of Activin that
directly decreases p-Erk(ERK)1/2 levels.
To identify the key effector that links the noncanonical Activin
pathway and p-Erk(ERK)1/2 inhibition, we selected several
potential proteins that negatively regulate levels of p-Erk and
tested for physical interactions with Alk4. We found that
PTP1B was the only one that satisfied both requirements. Our
data show that PTP1B is recruited to the Activin pathway by
binding to Alk(ALK)4, which mediates the cleavage of PTP1B.
Intriguingly, we find that Activin treatment also triggers an in-
crease in the number of physical interaction between PTP1B
and p-ERK1/2, which is abolished by SB431542. The interaction
of PTP1B/p-ERK1/2 leads the dephosphorylation of p-ERK1/2
and therefore the reduction of p-ERK1/2 levels. Our results are
in line with the role of PTP1B in dephosphorylating the insulin re-
ceptor EGF-R, MAPK, JNK, SH3-containing proteins (p130Cas,
Fak, and Crk) (Dadke and Chernoff, 2002; Jin et al., 2000), and
p-ERK1/2 (Ferrari et al., 2011; Haj et al., 2003). Our data suggest
that Activin induces the physical interaction between PTP1B and
p-ERK1/2 that leads to the inhibition of p-ERK1/2 signaling,
which is consistent with our findings that the inhibition of the
Activin pathway by SB431542 abolishes PTP1B/p-ERK1/2 inter-
actions and results in an increase in p-ERK1/2 levels. Here we
have shown that PTP1B mediates a noncanonical pathway of
Activin to regulate p-Erk(ERK)1/2 signaling. We have further
demonstrated that SB431542-mediated p-Erk(ERK)1/2 sig-
naling is decisive in neural specification by relieving the inhibitory
signal of the Activin/Alk(ALK)4 pathway. Most interestingly, the
phenomenon of PTP1B-regulated p-Erk(ERK)1/2 signaling also
occurs in ESCs during neural specification, in which period
PTP1B/p-Erk(ERK)1/2 interaction is absent in the cells undergo-
ing neural induction, suggesting that p-Erk(ERK)1/2 is critical
during neural specification. This finding is concomitant with pre-
vious reports that FGF/p-Erk(ERK)1/2 signaling promotes neural
specification in ESCs (Vallier et al., 2009a; LaVaute et al., 2009;
Na et al., 2010; Lin et al., 2010). Yoo et al. (2011) further showed
that the FGF-ERK1/2 signal pathway regulates neuroectoderm
specification through regulating PARP-1 activity. Despite most
studies supporting the promoting role of FGF signaling in neural
specification, some contradictory observations have been re-
ported. We reason that the discrepancy lies in the fashion ofCellFGF signaling manipulations during investigation (see details in
the supplemental legend for Figures S4B and S4C).
We generated PTP1B-OE and PTP1B-KD ESCs to evaluate
the actions of PTP1B in mediating Activin effects on the specifi-
cation of mesendoderm and on neural inhibition. Our results
showed that overexpressing PTP1B predisposes hESCs to
mesendodermal fates, whereas knocking down PTP1B results
in a bias toward neural fates. Recent studies suggested that
Activin/Nodal signaling acts via NANOG to block ESC differenti-
ation toward neural fate (Vallier et al., 2009b) and through SIP1
(Chng et al., 2010) to regulate the fate decision between neuro-
ectoderm and mesendoderm. Vallier et al. (2009b) reported
that NANOG knockdown promotes neural fate, while NANOG
overexpression blocks the effect even in the presence of
SB431542. Moreover, NANOG overexpression allowsmesendo-
derm specification but not further progression of endoderm
differentiation. They also showed that NANOG modulates the
activity of the Activin/Nodal pathway by binding to Smad2/3. In
our study, PTP1B mediates the action of Activin signaling via
ALK4, and PTP1B-OE only attenuates, but not obliterates, neural
fate. Furthermore, PTP1B-OE promotes mesendodermal fate,
but does not affect further progression of endoderm differentia-
tion. PTP1B-OE does notmaintain high levels ofNANOG expres-
sion during differentiation. Our study suggests that PTP1B acts
as an alternative pathway within the Activin/Alk(ALK)4 pathway
to determine the fate decision between neuroectoderm and
mesendoderm in hESCs andmESCs. These findings are in keep-
ing with our hypothesis that PTP1B acts as a downstream
effector of the Activin pathway. However, PTP1B did not fully
compensate for all functions of Activin/p-Smad(SMAD)2 sig-
naling in ESCs. For instance, unlike Activin, PTP1B-OE hESCs
did not maintain the high levels ofOCT4 andNANOG expression
during differentiation, indicating that PTP1B is not involved in the
p-Smad2-mediated expression of OCT4 and NANOG (Chng
et al., 2010; Lee et al., 2011). We propose that PTP1B takes
part in an Activin signaling pathway that is involved in regulating
mesendoderm fate decisions and that this role of PTP1B is
conserved in hESCs and mESCs.
In summary, our data suggest that Activin not only activates a
canonical p-Smad2 signaling cascade through Alk(ALK)4 but
also recruits PTP1B and triggers the interaction between
PTP1B and p-Erk(ERK)1/2. This interaction downregulates
p-Erk(ERK)1/2 signaling and leads to the inhibition of neural
induction. PTP1B also promotes mesendoderm specification,
possibly in cooperation with p-Smad2 signaling. Our study dem-
onstrates that PTP1B acts as a member of the Activin/Alk(ALK)4
pathway to regulate p-Erk(ERK)1/2 signaling, which forms
noncanonical signaling in Activin networks. Our study confers
PTP1B with a role in Activin-mediated functions in hESCs and
mESCs.
EXPERIMENTAL PROCEDURES
ESC Maintenance and ESC Monolayer Differentiation
Human ESCs (CCTL14) (passage numbers 25–30) were maintained on feeders
as previously described (Eiselleova et al., 2009) and plated onto Matrigel-
coated plates in conditioned media supplemented with 4 ng/ml FGF2 for three
to five passages before being used for all experiments. Mouse 46C ESCs (a gift
fromProf. A. Smith, Cambridge) weremaintained as previously described (Sun
et al., 2008 and Lin et al., 2010). Human and mouse ESCs were differentiatedStem Cell 13, 706–719, December 5, 2013 ª2013 Elsevier Inc. 717
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PTP1B Specifies Neural or Mesendodermal Fatetoward the neural lineage using a monolayer culture (hESCs on Matrigel-
coated plates and mESCs on gelatin-coated plates) in N2B27 medium or
chemically defined medium as previously described (Lin et al., 2010 and
Vallier et al., 2009a). We adopted the protocol (D’Amour et al., 2005) to
drive ESC differentiation toward definitive endododerm. The details of dif-
ferentiation experiments are described in the Supplemental Experimental
Procedures.
Quantitative Real-Time PCR
The cell samples collected from mESCs were analyzed by quantitative real-
time PCR using SYBR Green (Bio-Rad). Primer design and experimental pro-
cedures were carried out as previously described (Sun et al., 2005). Gene
expression levels were normalized to cyclophilin levels. The cell samples
collected from hESCs were measured by quantitative real-time PCR using
the TaqMan Gene Expression Assay (Applied Biosystems), and gene expres-
sion levels were normalized toGAPDH levels. All experiments were performed
in duplicate with two biological replicates.
PLA
PLA analysis was carried out according to the manufacturer’s instructions.
Fluorescent red dots were enumerated using MATLAB 7.11.0 software (The
MathWorks, Inc.) with the DIPimage toolbox extension and presented as
dots per nucleus. Sample preparation is described in the Supplemental Exper-
imental Procedures.
Immunocytochemistry
ESCs, NSCs, and neurons were fixed in 4% PFA for 20 min at room tempera-
ture. Antibodies against Oct4 (1:500, AB3209, Chemicon), Nes (1:500,
MAB353, Chemicon), Pax6 (1:500, Hybridoma bank), PTP1B (1:500, Santa
Cruz Biotechnology), Alk4 (1:500, Santa Cruz Biotechnology), and NeuN
(1:500, MAB377, Chemicon) were used.
Generation of PTP1B hESC Mutants
CCTL14 hESCs were used to generate PTP1B-KD and PTP1B-OE ESCs.
PTP1B-KD hESCs were generated by stable transfection with PTP1B shRNA
(TRCN0000002780) plasmid DNA (Sigma) under puromycin (0.3 mg/ml)
selection, while the control cells were transfected with a shRNA backbone
vector. PTP1B-KD hESCs were constitutively knocked down. PTP1B-OE
hESCs were created by stable transfection with a PTP1B-eGFP fusion vec-
tor, which was constructed in the pEF1a-AcGFP1-N1 vector (Clontech, BD
Biosciences), and were selected with G418 (100 mg/ml). The eGFP is fused
to the C terminus of PTP1B in this vector, and the sequences were verified
by sequencing.
Western Blot Analysis
To determine the temporal effects of SB431542 on p-Erk(ERK)1/2 levels,
SB431542 was added to mESCs and hESCs in ESC medium for 10 min,
30 min, 1 hr, 2 hr, 6 hr, 8 hr, and 1 day, and cells were harvested at each
time point. Other sample preparations are described in the Supplemental
Experimental Procedures.
Immunoprecipitation
To determine the biological function of PTP1B/p-ERK1/2 interactions, PTP1B
was immunoprecipitated from hESCs that were treated with Activin (10 ng/ml)
for 2 hr and incubated for 0, 10, 30, and 60 min with total protein, which was
isolated from hESCs treated with FGF2 for 10 min. The samples were
subjected to western blot analysis with an anti-p-ERK1/2 antibody.
Protein Sequencing
Protein sequencing was analyzed by LC/MS/MS, and chromatographic
separations were performed using an Ultimate LC system (Dionex). The
MS/MS analysis was conducted using collision energy profiles that were
chosen based on the mass-to-charge ratio (m/z) and the charge state of the
peptide. Sample preparation is described in the Supplemental Experimental
Procedures.718 Cell Stem Cell 13, 706–719, December 5, 2013 ª2013 Elsevier InPhospho-RTK and Phospho-MAPK Array Assay
The detailed steps were carried out according to the manufacturer’s protocol,
and sample preparation is described in the Supplemental Experimental
Procedures.
Statistical Analysis
Statistical significance was determined using a two-tailed Student’s t test.
p < 0.05 was considered statistically significant. All results are presented as
mean values ± SD from experiments that have been done three times.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes Supplemental Experimental
Procedures and seven figures and can be foundwith this article online at http://
dx.doi.org/10.1016/j.stem.2013.09.016.
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